IL13 and dermatitis herpetiformis, familial: By inhibiting IL-4/IL-13-mediated signaling, dupilumab can potentially reduce an inflammatory cascade by decreasing the function of T cells in lesional DH skin,8 as well as the infiltration of eosinophils and neutrophils into DH lesions.